Introduction
Recurrent respiratory papillomatosis (RRP) is a disease process of the airways that affects persons of all ages and is characterized by recurrent benign epithelial growths. The disease course can vary greatly between individuals. In many instances, spontaneous clearance occurs after only a few surgical procedures. In other cases, however, the papillomas continue to grow, spreading throughout the airway and ultimately affecting surgically inaccessible and untreatable areas, where eventual degeneration to squamous cell carcinoma portends the death of these patients. In this paper, we summarize the epidemiologic risk factors, viral-related pathogenesis, immunologic risks, and established treatment regimens for this debilitating disease.
Epidemiology
Papillomatosis of the human airway tract epithelia is a significant medical problem that has a prevalence rate of 3 to 5 per 100 000 population and accounts for at least $123 million per year in medical expense [1] [2] [3] [4] . The etiologic agent, human papillomavirus (HPV) types 6 and 11, can infect the entire respiratory tract, although the squamouscolumnar junction of the larynx is the most common site of involvement [5] . Airway involvement by other subtypes of HPV is very rare. Infection with HPV11 is more likely to be associated with the development of aggressive distal disease than HPV6 [1, 6, 7] . Another factor associated with distal spread of disease is diagnosis prior to the age of three [3,8 • 
Although RRP is very rare, exposure of the upper airway to HPV6 or HPV11 happens frequently during life. In fact, it is likely that exposure of the upper airway to HPV6 or HPV11 may be as common as exposure to other viruses such as rhinovirus; studies have shown that HPV DNA can be detected in the upper airway of as many as 25% of normal nonaffected children and adults [9, 10] . This frequency of exposure compounds the difficulty in identifying why some persons experience RRP but the majority do not. For example, exposure of a neonate to HPV during vaginal delivery to a mother affected with condylomata does occur [11, 12] ; however, the relative risk for the development of RRP is 7 in 1000, corresponding to an odds ratio of 231 compared with children born vaginally without condylomata [13] . This low risk has fueled a debate over whether cesarean section should be recommended in the presence of active condylomata, with some reports suggesting a higher rate of RRP in children delivered vaginally [13] and others citing a statistically higher rate in children delivered by cesarean section [9, 14] . For adult-onset RRP, oral sexual practices have been associated with a slightly higher risk for the development of papillomas [15] but have not been definitively implicated in disease pathogenesis. In general, given that the incidence of RRP is rare compared with the exposure risk to HPV6 or HPV11, other factors must contribute to the development of persistent papillomatous disease.
Viral pathogenesis
The virus has three vital components that cause human disease: (1) persistence causing a protracted disease course, (2) altered cellular growth resulting in airway papillomas, and (3) viral reproduction allowing the disease to spread. A clearer understanding of the factors that control viral genome persistence-associated cellular change and viral reproduction in human airway epithelium is critical to our understanding of disease pathogenesis and the development of novel treatment options.
Viral genome replication, maintenance and production
To cause long-standing disease, the HPV genome must persist during host cell division. In most papillomas, persistence is achieved as an episome (extrachromosomal circular HPV genome) [16,17 • ]. The maintenance and replication of this episomal genome under the nondifferentiating condition requires the expression of at least two early genes, E1 and E2. This vegetative state of reproduction is thought to represent the type of replication that occurs in nondifferentiated basal cells [18, 19] .
Part of the mechanism of episomal maintenance has been recently clarified. The viral gene E2 binds the viral genome to host chromosomal DNA so that it is segregated and maintained during mitosis [20 •• ]. When keratinocytes differentiate, the viral genome is amplified in the suprabasal cells by way of rolling-circle amplification that synthesizes a sufficient quantity of viral genome for packaging [21, 22] . This differentiation-dependent change in genome amplification has been linked to the expression of a late E1-E4 splice isoform. It has been hypothesized that cellular differentiation activates this late viral gene production, thus allowing assembly of virus [23] .
Much of what is currently known about HPV has been reported by the use of high-risk HPV16 and HPV31 in anogenital keratinocytes; the actual HPV6 or HPV11 mechanism of replication, maintenance, and viral production in airway cells is largely unexplored. For instance, it is still unknown whether airway cells produce infectious particles. More research focusing specifically on these low-risk HPV types in airway cells is needed to determine whether virus-airway cell interactions are similar to or different from disease in the anogenital area.
Altered cell growth
The mechanisms by which HPV produces a papillomatous growth are also poorly understood. In cells with high-risk HPV16 genomes, the development of condylomata requires an alteration in cellular growth and differentiation. Two key viral genes responsible for this change in growth and differentiation are E6 and E7. These proteins bind to and alter the function of two key apoptotic proteins, Rb and P53 [5, 24, 25] . The E6 and E7 from HPV6 and HPV11 do not readily degrade these key cellular genes [26,27,28 • ], however, which implies that the mechanisms leading to altered growth in the airway are likely different.
Significant data also suggest that the presence of HPV6 or HPV11 in airway epithelial cells is not sufficient alone to induce papillomatous growth, because biopsy specimens from normal mucosa of the distal airway and separate from sites of papilloma also contain HPV genomes [29,30 • ]. Several authors have hypothesized that the virus may remain in a latent state [29,30 • ], although the factors that activate papilloma growth in virus-infected normal cells remain unknown. Like the factors controlling viral replication, the mechanisms required for altered cellular differentiation by HPV6 or HPV11 in airway cells require more basic research so that mechanism-specific treatment strategies can be developed.
Immune relationship
It is probable that most persons have been exposed to, or infected with, low-risk HPV viruses. As with most viruses; the disease course for each person varies. Most persons clear the virus exposure completely, but in some individuals the virus persists. In a fraction of this latter group, disease becomes active and papillomas form. One possible reason for viral persistence may be the inability to present viral antigens in major histocompatibility complexes (MHCs). Population studies have identified certain MHC alleles that are found in a higher percentage of RRP patients than in the general population [31, 32] . Despite this association, however, HPV persistence requires more than a specific MHC allele, because many people with at-risk alleles do not develop disease.
Part of the answer may be related to the ability of HPV to downregulate the immune response. Recent work has shown that the low-risk HPV viral protein E7 interacts with TAP-1, resulting in a decrease in this protein in the infected cell. Because TAP-1 plays an important role in shuttling antigen from a proteasome to the endoplasmic reticulum, where it assembles with the MHC, a decrease in TAP-1 may make a cell more tolerant to HPV infection [33] . These findings suggest that immune modulation is likely to play a role in the ability of HPV to persist, although this association also raises the question why so many people are able to clear the virus.
Surgical approaches
No disease-specific definitive medical therapy exists for RRP; therefore, multiple palliative surgical procedures are required to remove the papillomas. Several principles hold regarding papilloma removal. First, in contradistinction to malignant lesions, with HPV, margins should not be obtained. Multiple studies have shown that HPV is present in the normal mucosa [9,10] and it is currently not possible to distinguish infected cells with a normal appearance from unaffected epithelia. Second, although pathologic confirmation of the diagnosis should be established at the first resection, repeat biopsy is not indicated with every procedure but should be obtained at defined intervals to evaluate for disease progression to cancer. Third, every attempt to maintain laryngeal function is crucial. This dictum may require leaving residual disease to prevent anterior or posterior web formation. Last, tracheostomy should be avoided because this procedure is associated with a substantially increased risk of distal tracheal spread [34, 35] .
The techniques to remove papillomas have evolved over time. The use of the operating microscope first provided improved functional outcomes for patients with RRP by increasing visibility. With the advent of laser surgery, ablation of papillomas in a relatively blood-free field became possible [36] . Today, a laryngeal and tracheal microdebrider blade has replaced laser ablation as first-line surgical therapy. This change reflects a safety perspective (there is no risk of airway fire or inadvertent laser injury with the debrider), a cost perspective (the microdebrider is much less expensive to use because operating room time is decreased and fewer personnel are needed), and an outcome perspective (functional studies have shown improved functional outcome with the microdebrider in comparison with the laser [37, 38] 
Adjuvant therapies
Because of the rarity and clinical variability of RRP, proving efficacy for adjuvant therapies requires well-designed studies that are properly controlled. Unfortunately, most therapies that are used have not been rigorously tested and are described only in small series or as anecdotal case reports without proper controls.
a-Interferon
The use of a-interferon has been the most extensively investigated adjuvant therapy for RRP. a-Interferon has the theoretic benefits of modulating both the immune system and epithelial development. The results of a doubleblinded placebo-controlled study for RRP showed a dosedependent decrease in severity for papilloma growth over the first 6 months of therapy [40, 41] . Unfortunately, cessation of therapy quickly resulted in disease relapse to pretherapy growth rates. In addition, significant side affects were encountered with prolonged use [39 • ].
Indole-3-carbinol
Indole-3-carbinol (I3C) has been approved by the United States Food and Drug Administration as a nutritional supplement; it is found in high concentrations in cruciferous vegetables like broccoli, cabbage, and cauliflower. It alters estrogen metabolism by shifting the p450-dependent hydroxylation of estrone from 16 a-hydroxyestrone to 2-hydroxyestrone, which in turn alters cellular proliferation and DNA synthesis [42] . In animal models, 2-hydroxyestrone inhibits the estrogen-dependent growth of tumors [43] , and because the viral life cycle is interconnected with epithelial differentiation, several investigators have hypothesized that I3C would decrease RRP disease burden.
Although several reports have shown that treatment with I3C may be beneficial, these studies were not prospective randomized placebo-controlled trials, and the potential efficacy of I3C should be viewed with caution [44 • ]. Importantly, the supplement is safe and has virtually no side affects [44 • ]. Both the possible benefit and the mechanism of benefit for I3C need well-designed studies before it can be recommended as a true therapy for RRP patients.
Cidofovir
Ideally, a drug that specifically targets the HPV genome for removal would cure RRP without causing concomitant cell damage to uninfected cells. Currently, a pharmaceutical inhibitor that is approved specifically for HPV infection is not available. Initial trials using the cytosine analog cidofovir (1-[(S)-3-hydroxy-2 (phosphonomethoxy) propyl] cytosine dihydrate) have been undertaken [45] [46] [47] [48] [49] . Cidofovir has been approved by the United States Food and Drug Administration to treat cytomegalovirus retinitis in AIDS patients. The mechanism of action for this drug in cytomegalovirus is through selective inhibition of the herpesvirus DNA polymerase [50] . In these cytomegalovirus-infected cells, cidofovir inhibits herpes DNA polymerase at least two times more potently than human DNA polymerase, thus leading to selective inhibition of viral replication [50] . HPV does not encode a viral polymerase, however; instead, it uses host cell DNA polymerase to replicate the viral genome. This constraint means that the mechanism of action of cidofovir in HPV cells cannot be selective inhibition of a viral polymerase. Nevertheless, an initial trial of cidofovir for treatment of papilloma formation in the cottontail rabbit papillomavirus model showed promising inhibition of papilloma growth [51] . Initial reports in small noncontrolled clinical studies have also suggested some usefulness [47, 48, 52] .
The utility of this cytosine analog in the treatment of HPV-infected cells in vitro has been evaluated. Both transformed cells and cancer cells containing integrated HPV have shown preferential growth inhibition with cidofovir in comparison with non-HPV cancer cells. These studies suggest a selective method of cidofovir-mediated toxicity when cell death in immortalized HPV-positive cells is compared with that in either HPV-negative immortalized cells or primary keratinocytes [53] [54] [55] . These studies, however, did not attempt to correlate cell replication rates to cidofovir toxicity. Recent work has made an attempt to understand a mechanism of action for cidofovir in HPV-containing cells [56 •• ] . It has been shown that cidofovir is incorporated into episomal DNA at a slightly higher rate than genomic DNA, and cidofovir may slightly inhibit viral genome replication in comparison with human genome replication. Replication of the viral genome quickly returns to baseline after drug removal, however.
The transient nature of this inhibition suggests that any clinical application aimed at inhibition of viral genome replication using cidofovir would require prolonged exposure and frequent administration; thus, the potential for carcinogenic side effects would be increased. Recent studies [56 •• ] have shown that papilloma cells were more sensitive to cidofovir than normal cells; however, the mechanism was related to incorporation during rapid cell turnover rather than by way of an HPV-selective mechanism. Like all cytosine analogs, cidofovir primarily blocks DNA replication through incorporation into the genome, thus preferentially targeting rapidly dividing cells. Multiple rapidly dividing cell lines derived from cancers not related HPV infection have been shown to be sensitive to the cytotoxic effects of cidofovir, such as B16 melanoma, hemangiosarcoma, and nasopharyngeal carcinoma [57] [58] [59] [60] . Therefore, it is likely that cidofovir kills papilloma cells more effectively than normal cells in the surgical wound because the papilloma cells are dividing more rapidly and are susceptible to cidofovir.
Clinical therapy of cidofovir to induce non-HPV-specific cell death in the more rapidly dividing cells of a papilloma may have clinical utility; however, multiple studies have challenged the safety of using this compound. Prolonged therapy has identified several potential adverse effects, including renal toxicity [61] [62] [63] and adenocarcinomas developed in rats that were given the equivalent human dose over 26 weeks [63] . Besides these in-vivo results, several in-vitro assays have predicted that cidofovir is a carcinogen [64] . Possible additional carcinogenic effects in HPV-containing cells, lacking normal p53 and pRb, have not been investigated. Prior to noninvestigational use, cidofovir needs further studies aimed at elucidating a potential mechanism of cell death specific to HPV and properly controlled studies aimed at testing efficacy and safety.
Vaccine
Recent vaccination trials investigating the persistence of HPV16 in cervical cells has suggested that immunization with viral coat proteins can protect against infection [65 •• -67 •• ]. These breakthrough studies suggest that HPV16 diseases can be prevented with immunization. Although this approach is promising for prevention, its feasibility for use with established HPV disease is untested. Many questions remain before immunization strategies can be determined to be helpful for RRP. For example, differences between RRP and cervical HPV disease include age at exposure, viral type, and disease progression, all issues that must be considered when an immunization strategy for RRP is designed and planned.
In a recent multi-institution study using a vaccination strategy to develop an immune response to established RRP disease [68] , participants were vaccinated with an immune modulating heat shock protein linked to the E7 protein of HPV16. In preclinical mouse models, similar strategies were able to eradicate established diseases in mice by improving cellular and humoral immunity to viral antigens, thus allowing mice to clear viral-infected cells [69] [70] [71] . In the human trial, 27 RRP patients received three sequential injections with 500 mcg of HPV-E7 protein, with an observed increase in surgical intervention time and safety. As with most therapies aimed at RRP, however, the response varied on an individual basis: two persons required no further therapy after the vaccination, and approximately 40% of patients had at least one surgical intervention lengthened [2] . No severe adverse reactions were encountered. This strategy warrants further study, including a study design with a placebo-control arm and the creation of a vaccine composed of heat shock protein linked to the viral proteins of HPV6 and HPV11. Although HPV16 E7 protein has some similarity (;40%) with the HPV6 or HPV11 protein and antigen crossover may occur, using the correct antigen would more likely give a stronger and more specific response. As stated earlier, it is likely that the HPV virus decreases antigen presentation; therefore, immuneenhancing strategies such as these hold great promise for the treatment of established RRP.
Conclusion
Recurrent respiratory papillomatosis is a rare disease that carries severe morbidity and occasional mortality. Improvements in surgical approaches have slightly improved the overall care of these patients; however, cure is possible only with disease-specific medical therapy. To that end, more research is needed to understand how HPV causes disease so that these therapies can be developed.
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